The ATAD2 Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal cell population featuring targeted disruption of the ATAD2 gene. This polyclonal knockout model is derived from the A-549 human lung adenocarcinoma cell line and provides a heterogeneous pool of edited alleles, enabling researchers to study loss-of-function phenotypes without clonal selection biases. The gene disruption is introduced via CRISPR/Cas9-mediated non-homologous end joining, generating a mixed population that reflects the diversity of editing outcomes. This format is particularly suited for pooled screening approaches, bulk functional assays, and studies requiring rapid generation of knockout models without the need for single-cell clone isolation. The cells are validated at the population level for target protein depletion, ensuring a reliable and reproducible tool for downstream applications.
The host cell line A-549 is a widely used model of human lung adenocarcinoma, originally established from the tumor tissue of a 58-year-old male. These epithelial cells exhibit characteristics typical of type II pulmonary epithelium, including the formation of tight junctions and expression of surfactant proteins. A-549 cells are extensively employed to study lung cancer biology, epithelial barrier function, and xenobiotic metabolism, particularly the activity of cytochrome P450 enzymes. Their robust growth in culture and well-characterized signaling networks make them a versatile platform for knockout studies. In lung cancer research, A-549 cells recapitulate key features of the disease, including mutated KRAS and dysregulated p53, providing a clinically relevant context for investigating oncogenic pathways and therapeutic targets.
ATAD2 (ATPase family AAA domain-containing protein 2) is a chromatin-regulating AAA+ ATPase that functions as a transcriptional coactivator for steroid hormone receptors and the MYC oncoprotein. It is activated by estrogen and androgen signaling, as well as by the transcription factors MYC and E2F1, which are key drivers of cell cycle progression. ATAD2 interacts directly with estrogen receptor alpha (ER??), androgen receptor (AR), and MYC, and is a component of the SRCAP chromatin remodeling complex. Once recruited to chromatin, ATAD2 promotes the expression of genes involved in cell proliferation and survival, including cyclin D1, MYC transcriptional targets, and other cell cycle regulators. This activity places ATAD2 at the nexus of oncogenic signaling, where it integrates upstream mitogenic signals to drive G1/S transition through the pRB-E2F pathway, often cooperating with CDK4/6 activity to overcome cell cycle checkpoints.
In the A-549 lung cancer background, ATAD2 knockout is particularly informative given the gene’s frequent overexpression in lung adenocarcinomas and its correlation with poor patient prognosis. Loss of ATAD2 function in this model likely disrupts the transcriptional programs that sustain unchecked proliferation, potentially sensitizing cells to targeted therapies or chemotherapeutic agents. The model enables dissection of ATAD2’s role in maintaining the malignant phenotype of lung cancer cells, including its contributions to cell cycle deregulation, apoptosis resistance, and migratory capacity. By ablating ATAD2 within the A-549 context, researchers can directly assess its necessity for tumorigenic properties in a cell line that harbors other common lung cancer alterations, thereby evaluating the relative dependency of these cells on ATAD2-driven pathways.
Researchers can employ this polyclonal knockout population in a wide array of functional assays to interrogate ATAD2 biology. Typical applications include monitoring cell proliferation and viability via MTT or colony formation assays, assessing apoptosis by flow cytometry, and profiling cell cycle distribution after ATAD2 disruption. Migration and invasion assays on these cells can reveal the impact of ATAD2 loss on metastatic potential, while drug sensitivity testing can identify synthetic lethal interactions or new therapeutic vulnerabilities. Gene expression analysis by RT-qPCR and western blotting, combined with chromatin immunoprecipitation (ChIP-qPCR), enables mechanistic studies of ATAD2-dependent transcriptional regulation. These cells are an invaluable resource for cancer biology, steroid receptor signaling research, and preclinical drug target validation. For additional information or technical support, please contact Ascent Research.
